San Diego, California — June 10, 2010. Solulink, Inc., a leading innovator of state-of-the-art
conjugation reagents, easy-to-use reproducible linking kits, and conjugation services for the life
science research, diagnostics, and pharmaceutical markets, today announced it has been
awarded a $600,000 SBIR Phase I grant from the National Institute of Allergy and Infectious
Diseases (NIAID) to develop a Multiplexed Vaccine Titer Assay.
The increasing range and multivalency of vaccines has created a need for cost-effective, highly
multiplexed serological testing to determine antibody response to each component. New tests
are needed both as screening assays to evaluate protection of each patient and as a tool for
vaccine development to detect efficacy for each target in novel combinations. Existing multiwell
ELISA immunoassay protocols are laborious and poorly matched to multi-analyte testing.
Solulink, in collaboration with Professor Stephen Kron and his team in the Department of
Molecular Genetics and Cell Biology, University of Chicago’ will apply its proprietary protein
multiplex technology to develop a multiplex vaccine titer test. David Schwartz, Ph.D., Solulink’s
Chief Science Officer and Principal Investigator for the project stated, “We are pleased that
SBIR has awarded us the opportunity to demonstrate the ability of our platform technology to
develop a multiplexed vaccine titer assay. With this grant we propose to develop a single assay
to quantify responses to each component of a multi-analyte vaccine.”
The Small Business Innovation Research Program (SBIR) works to ensure that the nation’s
small, high-tech, innovative businesses act as a significant part of the federal government’s
research and development projects. In reviewing grant applications the SBIR seeks unique
research projects that are of high scientific caliber that are relevant to public health needs.
SBIR Grant 1 R43 AI91340-01
Solulink’s proprietary conjugation reagents and easy-to-use linking kits provide unique features
and benefits used to link proteins, oligonucleotides, peptides, and antibodies to each other or to
a wide range of surfaces including beads, chips, and slides. Solulink has developed several
lines of products that incorporate its technology including streptavidin magnetic and agarose
beads that have the highest binging capacity on the market, ChromaLink Biotin with a built in
quantification feature, antibody labeling kits, oligo and peptide synthesis reagents. Solulink
markets its products both directly and through distributors and licensing partners worldwide.
Solulink is a privately held company located in San Diego, California. For more information,
please visit www.solulink.com.
9853 Pacific Heights Blvd. Suite H,
San Diego, California 92121